New immune therapy targets Hard-to-Treat blood cancers
NCT ID NCT07312630
First seen Jan 06, 2026 · Last updated May 14, 2026 · Updated 23 times
Summary
This early-phase study tests a new treatment called LV009 injection for people with certain blood cancers (non-Hodgkin lymphoma and acute lymphoblastic leukemia) that have not responded to standard therapy or have returned. The treatment uses the patient's own immune cells, modified to attack cancer cells carrying a protein called CD19. The main goal is to check safety and how the therapy behaves in the body, with 19 participants aged 18 to 70.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
PersonGen.Anke Cellular Therapeutice Co., Ltd.
RECRUITINGHefei, Anhui, 230088, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.